囊性纤维化肝胆受累:诊断与监测中的影像学进展
本文综述囊性纤维化肝胆受累(CFHBI)的影像学诊断与监测进展。随着高效囊性纤维化跨膜受体蛋白(CFTR)调节剂使约80%的患者获益,CFHBI的评估因药物代谢和寿命延长带来的肝内血管改变而更趋复杂。文章涵盖弹性成像、超声和磁共振成像在CFHBI及其并发症诊断与监测中的应用与需求,强调需结合血清生物标志物与影像学,并应从儿童期开始诊断与监测。
要点
- 约80%的囊性纤维化患者适合高效CFTR调节剂治疗,肝受累评估需考虑药物代谢影响。
- CFHBI诊断与监测需结合血清生物标志物与影像学,并应从儿童期开始。
- 弹性成像、超声和MRI用于诊断与监测CFHBI及其相关并发症。
核心结论
- 囊性纤维化肝胆受累的诊断与监测需结合血清生物标志物与影像学,影像学(包括弹性成像、超声和MRI)在诊断CFHBI及其相关并发症中具有重要作用,且应从儿童期开始。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
临床应用与阅片要点
- 部分囊性纤维化患者会发展为至少CFHBI,其中一部分会进展为晚期囊性纤维化相关肝病(aCFLD),诊断和监测需从儿童期开始。
- 高效CFTR调节剂治疗使约80%的囊性纤维化患者获益,肝受累评估需兼顾药物代谢与固有CFHBI及寿命延长相关的肝内血管改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Analysis of the liver using imaging for persons with cystic fibrosis (CF) continues to evolve as new medical therapies are developed improving and extending life. In the 2010s, therapies targeted at modulating protein folding became available to those with CF. Therapeutic options have continued to expand, now providing both correction of protein folding and stabilization for most gene mutations that code for the CF transmembrane receptor protein (CFTR). Today, approximately 80% of persons with CF are eligible for highly effective modulator therapy. With these advancements, the impact of CF on the liver has become more complex, adding metabolism of CFTR modulators to intrinsic CF hepatobiliary involvement (CFHBI) and adding not previously appreciated vascular changes within the liver due to increased longevity in persons with CF. A combination of serum biomarkers and imaging is needed to add clarity to the diagnosis and monitoring of the severity of liver disease. A substantial portion of persons with CF will develop at least CFHBI and a subset will develop advanced cystic fibrosis-associated liver disease (aCFLD); therefore, diagnosis and monitoring need to begin in childhood. In this review, we cover the use of and need for imaging, including elastography, ultrasound, and magnetic resonance imaging (MRI), in diagnosing and monitoring CFHBI and its associated complications.
引用
- Wood W, Tinich T, Lazar L, et al. Cystic fibrosis hepatobiliary involvement: an update on imaging in diagnosis and monitoring. Pediatr Radiol. 2024. PMID: 39039200. doi:10.1007/s00247-024-05979-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。